Company Description
PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States.
Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.
The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment.
The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015.
PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Joshua Silverman |
Contact Details
Address: 3960 Howard Hughes Parkway, Suite 500 Las Vegas, Nevada 89169 United States | |
| Phone | 917-595-2850 |
| Website | pharmacyte.com |
Stock Details
| Ticker Symbol | PMCB |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0001157075 |
| CUSIP Number | 71715X203 |
| ISIN Number | US71715X2036 |
| Employer ID | 62-1772151 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Joshua N. Silverman | Interim Chief Executive Officer, Interim President and Interim Chairman |
| Carlos A. Trujillo CPA, CPA | Chief Financial Officer |
| Dr. Jose L. Iglesias M.D. | Consulting Chief Medical Officer |
| Dr. Hans-Peter Hammes | Member of Medical and Scientific Advisory Board and Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 17, 2024 | 10-Q | Quarterly Report |
| Sep 17, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Aug 13, 2024 | 10-K | Annual Report |
| Jul 29, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| May 30, 2024 | 3 | Initial statement of beneficial ownership of securities |
| May 23, 2024 | 8-K | Current Report |
| May 1, 2024 | 8-K | Current Report |
| Mar 27, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2024 | ARS | Filing |